View in EDS

First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors.

Saved in:

Bibliographic Details
Title:	First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors.
Authors:	Siu LL; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Electronic address: lillian.siu@uhn.ca., Gutierrez ME; Hackensack University Medical Center, Hackensack, USA., Pudelko L; Merck Healthcare KGaA, Darmstadt, Germany., Ruth K; Merck Healthcare KGaA, Darmstadt, Germany., Filho MAFN; Merck Healthcare KGaA, Darmstadt, Germany., Zaynagetdinov R; EMD Serono Research & Development Institute Inc, Billerica, USA, an affiliate of Merck KGaA., Hu P; EMD Serono Research & Development Institute Inc, Billerica, USA, an affiliate of Merck KGaA., Kitzing T; Merck Healthcare KGaA, Darmstadt, Germany., Guenhan BK; Merck Healthcare KGaA, Darmstadt, Germany., Durutovic I; Merck Healthcare KGaA, Darmstadt, Germany., McKean M; Sarah Cannon Research Institute (SCRI), Nashville, USA.
Source:	ESMO open [ESMO Open] 2026 May; Vol. 11 (5), pp. 106962. Date of Electronic Publication: 2026 May 07.
Publication Type:	Journal Article; Clinical Trial, Phase I; Multicenter Study
Journal Info:	Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2059-7029
DOI:	10.1016/j.esmoop.2026.106962